# Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2016

- Company: [Protalix BioTherapeutics, Inc.](/companies/plx.md) (CIK 1006281)
- Form: 10-Q
- Filed: 2016-08-08
- Accepted by EDGAR: Aug 8, 2016, 16:51 ET
- Period: 2016-06-30
- Accession: 0001144204-16-117287
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006281/000114420416117287/v445418_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006281/000114420416117287/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-04-01 to 2016-06-30 | $1.8m | us-gaap:Revenues |
| Revenue | 6 months, 2016-01-01 to 2016-06-30 | $2.4m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-04-01 to 2016-06-30 | $1.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2016-01-01 to 2016-06-30 | $2.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-04-01 to 2016-06-30 | $94.0k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2016-01-01 to 2016-06-30 | $250.0k | us-gaap:GrossProfit |
| Research and development | 3 months, 2016-04-01 to 2016-06-30 | $10.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2016-01-01 to 2016-06-30 | $17.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-04-01 to 2016-06-30 | $2.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2016-01-01 to 2016-06-30 | $4.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-04-01 to 2016-06-30 | −$9.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-01-01 to 2016-06-30 | −$17.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2016-04-01 to 2016-06-30 | −$10.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2016-01-01 to 2016-06-30 | −$19.5m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months, 2016-01-01 to 2016-06-30 | −$21.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2016-01-01 to 2016-06-30 | $575.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-06-30 | $54.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-06-30 | $67.6m | us-gaap:AssetsCurrent |
| Total assets | at 2016-06-30 | $78.9m | us-gaap:Assets |
| Current liabilities | at 2016-06-30 | $11.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-06-30 | $86.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-06-30 | −$8.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1006281/000114420416117287/v445418_10q.htm

Filed Aug 8, 2016.
Source: SEC EDGAR, the filing index for accession 0001144204-16-117287. Last ingested by Listed: Nov 10, 2026, 16:48 ET. No prices; not investment advice.
